Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
This study aimed to test the antiproliferative effect of three benzimidazole anthelmintics in intestinal cancer cells and to investigate whether these drugs, which inhibit tubulin polymerization, can potentiate the efficacy of the microtubule-stabilizing drug paclitaxel (PTX). Four intestinal cancer cell lines, SW480, SW620, HCT8, and Caco2, with different origins and growth characteristics were used. The antiproliferative effect of albendazole (ABZ), ricobendazole (RBZ), flubendazole (FLU), and their combinations with PTX was tested using three different end-point viability assays, cell cycle distribution analysis, and the x-CELLigence System for real-time cell analysis. ABZ and FLU inhibited cell proliferation significantly in a concentration-dependent and time-dependent manner through cell arrest in the G2/M phase. RBZ was not effective at any concentration tested. The cell lines differed in sensitivity to FLU and ABZ, with HCT8 being the most sensitive, showing IC₅₀ values for ABZ and FLU that reached 0.3 and 0.9 μmol/l, respectively. Combinations of PTX+ABZ and PTX+FLU decreased cell viability more effectively when compared with treatment with individual drugs alone. The anthelmintic benzimidazole drugs ABZ and FLU show a significant cytostatic effect and potentiate the efficacy of PTX in intestinal cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lacey, E. (1988) · International Journal for Parasitology · doi:10.1016/0020-7519(88)90175-0 · Cited by 560
Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics
Dayan, A. D. (2003) · Acta Tropica · doi:10.1016/s0001-706x(03)00031-7 · Cited by 371
In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole
Pourgholami, M. H., Woon, L., Almajd, R., Akhter, J., Bowery, P., & Morris, D. L. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00382-2 · Cited by 139
Albendazole sensitizes cancer cells to ionizing radiation
Patel, K., Doudican, N. A., Schiff, P. B., & Orlow, S. J. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-160 · Cited by 66
Cited by
Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
Nygren, P., Fryknäs, M., Ågerup, B., & Larsson, R. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1539-5 · Cited by 133
The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs
Son, D.-S., Lee, E.-S., & Adunyah, S. E. (2020) · Immune Network · doi:10.4110/in.2020.20.e29 · Cited by 130
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics
Song, B., Park, E. Y., Kim, K. J., & Ki, S. H. (2022) · Cancers · doi:10.3390/cancers14194601 · Cited by 55
Metadata
- Authors
- Králová, V., Hanušová, V., Staňková, P., Knoppová, K., Čáňová, K., & Skálová, L.
- Venue
- Anti-Cancer Drugs
- Published
- 2013-10
- Volume
- 24
- Issue
- 9
- Pages
- 911-919
- ISSN
- 0959-4973 (ISSN-L)
- OpenAlex
- W2320744367
- Cited by
- 66
- References
- 4
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines. https://app.cochat.ai/papers/10.1097/cad.0b013e3283648c69
- The paper
- Králová, V., Hanušová, V., Staňková, P., Knoppová, K., Čáňová, K., & Skálová, L. (2013). Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines. Anti-Cancer Drugs. https://doi.org/10.1097/cad.0b013e3283648c69
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.